ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market.Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
Harmony Biosciences Holdings, Inc. (HRMY) stock declined over -4.80%, trading at $30.97 on NASDAQ, down from the previous close of $32.53. The stock opened at $32.01, fluctuating between $30.75 and $32.25 in the recent session.
Plymouth Meeting, PA 19462
United States
Website: https://www.harmonybiosciences.comContact: 484 539 9800Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Employees | 268 |
Beta | 0.82 |
Sales or Revenue | $582.02M |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |